MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway

MD-2 binds cholesterol

(2016) Soo-Ho Choi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

MCP-1-induced protein attenuates post-infarct cardiac remodeling and dysfunction through mitigating NF-κB activation and suppressing inflammation-associated microRNA expression

(2015) Jianli Niu et al.   BASIC RESEARCH IN CARDIOLOGY

MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis

(2015) Yi Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling

(2015) R. A. Frieler et al.   CIRCULATION

Recent Developments in Heart Failure

(2015) Sujith Dassanayaka et al.   CIRCULATION RESEARCH

Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells

(2015) Anand R. Nair et al.   EXPERIMENTAL CELL RESEARCH

Anti-toll like receptor 4 (TLR4) therapy diminishes cardiac remodeling regardless of changes in blood pressure in spontaneously hypertensive rats (SHR)

(2015) Cinthya Echem et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4

(2015) Susumu Matsuda et al.   Journal of Atherosclerosis and Thrombosis

MD-2 is required for disulfide HMGB1–dependent TLR4 signaling

(2015) Huan Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The war against heart failure: the Lancet lecture

(2015) Eugene Braunwald   LANCET

Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction

(2014) Dong Fan et al.   CARDIOVASCULAR RESEARCH

Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension

(2014) Rahul B. Dange et al.   CARDIOVASCULAR RESEARCH

Targeting myeloid differentiation 2 for treatment of sepsis

(2014) Guangjie Duan   Frontiers in Bioscience-Landmark

Cardiovascular remodelling in coronary artery disease and heart failure

(2014) Gerd Heusch et al.   LANCET

Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation

(2013) Lei Wang et al.   CARDIOVASCULAR RESEARCH

Solving the Cardiac Hypertrophy Riddle

(2013) Daniela Zablocki et al.   CIRCULATION RESEARCH

Signal Regulatory Protein-α Protects Against Cardiac Hypertrophy Via the Disruption of Toll-Like Receptor 4 Signaling

(2013) Ding-Sheng Jiang et al.   HYPERTENSION

Serum Amyloid A3 Binds MD-2 To Activate p38 and NF- B Pathways in a MyD88-Dependent Manner

(2013) A. Deguchi et al.   JOURNAL OF IMMUNOLOGY

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

(2013) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Angiotensin II Facilitates Fibrogenic Effect of TGF-β1 through Enhancing the Down-Regulation of BAMBI Caused by LPS: A New Pro-Fibrotic Mechanism of Angiotensin II

(2013) Yu-Sheng Li et al.   PLoS One

HIV-1 Tat protein binds to TLR4-MD2 and signals to induce TNF-α and IL-10

(2013) Nawal Ben Haij et al.   Retrovirology

New Take on the Role of Angiotensin II in Cardiac Hypertrophy and Fibrosis

(2011) Mazen Kurdi et al.   HYPERTENSION

Angiotensin II–Induced Hypertension Is Modulated by Nuclear Factor-κB in the Paraventricular Nucleus

(2011) Jeffrey P. Cardinale et al.   HYPERTENSION

MD-2 as the Target of Nonlipid Chalcone in the Inhibition of Endotoxin LPS-Induced TLR4 Activity

(2011) Eunmiri Roh et al.   JOURNAL OF INFECTIOUS DISEASES

Targeting of Toll-like receptors: a decade of progress in combating infectious diseases

(2011) Mona Hedayat et al.   LANCET INFECTIOUS DISEASES

Inflammatory cytokines in vascular dysfunction and vascular disease

(2009) Alexander H. Sprague et al.   BIOCHEMICAL PHARMACOLOGY

Angiotensin II Induces Inflammatory Response Partly Via Toll-Like Receptor 4-Dependent Signaling Pathway in Vascular Smooth Muscle Cells

(2009) Yuanyuan Ji et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

PPARγ agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway

(2009) Yuanyuan Ji et al.   LABORATORY INVESTIGATION

Involvement of Tumor Necrosis Factor-α in Angiotensin II–Mediated Effects on Salt Appetite, Hypertension, and Cardiac Hypertrophy

(2008) Srinivas Sriramula et al.   HYPERTENSION

Metallothionein Suppresses Angiotensin II–Induced Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activation, Nitrosative Stress, Apoptosis, and Pathological Remodeling in the Diabetic Heart

(2008) Guihua Zhou et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction

(2007) Leo Timmers et al.   CIRCULATION RESEARCH